Dr. Ajay Bose works in a lab with three students in a vintage photo.

The Ajay Bose Hall of Distinction

Celebrating a Legacy of Discovery

Honoring the scientists, educators and leaders whose work has shaped chemistry and chemical biology at Stevens and made an impact around the world.


Exterior of McLean Hall.Located in McLean Hall, the Ajay Bose Hall of Distinction honors the scientists, educators and leaders whose work has extended the impact of chemistry and chemical biology far beyond the Stevens campus.

Established in 2026, the Hall begins with Professor Ajay Kumar Bose and three distinguished Stevens alumni whose careers have advanced scientific discovery, pharmaceutical research and the development of new medicines.

Their achievements reflect the enduring influence of a Stevens education and the power of mentorship to shape generations of scientists and innovators.

Established 2026 · Inaugural honorees inducted September 2026


Dr. Ajay Kumar Bose.

THE LEGACY BEHIND THE HALL: Dr. Ajay Kumar Bose

A pioneer in organic chemistry, chemical biology and mentorship, Dr. Ajay Kumar Bose (1925–2010) spent nearly five decades at Stevens, starting in 1959 until 2007. His pioneering research and dedication to mentorship helped shape generations of scientists, physicians and engineers. His work in beta-lactam antibiotics and green chemistry contributed to a lasting legacy in organic chemistry and chemical biology. At Stevens, he also developed visionary educational initiatives including the Undergraduate Projects in Technology and Medicine (UPTAM) and Chemical Biology programs, giving students opportunities to explore connections among chemistry, medicine and technology.

The Inaugural Honorees

Joining Professor Ajay Kumar Bose as an inaugural honoree are three distinguished Stevens alumni whose careers have advanced scientific discovery, pharmaceutical research and the development of new medicines:

Jeffrey Hale.Dr. Jeffrey J. Hale ’85

Associate Vice President, Discovery Chemistry, Merck Research Laboratories, Retired

From Stevens chemistry to pharmaceutical discovery

Jeffrey J. Hale, Ph.D., is an Adjunct Professor at the Ernest Mario School of Pharmacy at Rutgers University and has more than 40 years of experience in medicinal chemistry and the pharmaceutical industry. His career includes a distinguished 36-year tenure at Merck Research Laboratories, where he retired in 2021 as Associate Vice President of Discovery Chemistry. At Merck, Hale led small-molecule discovery and development programs targeting cardiometabolic and immunoregulatory disorders. He also contributed to medicinal chemistry efforts across Merck’s infectious diseases, neuroscience and oncology programs.

Hale’s work has resulted in more than 70 peer-reviewed publications and 43 issued U.S. patents. In 2005, he received the Society of Chemical Industry’s Gordon E. Moore Medal for his contributions leading to the discovery and commercialization of the NK1 receptor antagonist Emend®.

Hale earned a B.S. in Chemistry from Stevens Institute of Technology in 1985 and a Ph.D. in Chemistry from Rutgers University in 1992.

Inaugural honoree · September 3, 2026

Q&A with Dr. Hale

Q: What are your strongest memories of your time spent at Stevens?

Dr. Hale: While I have many memories of my time at Stevens, the strongest is that I met my future wife Audrey (Ajalat) during our freshman year (1981). We’ll be celebrating our 39th wedding anniversary on August 16. While that isn’t directly related to Stevens chemistry or science, it’s undoubtedly the thing that has had the most impact on my life.

Q: What was the focus of your graduate/undergraduate research at Stevens?

Dr. Hale: As an undergraduate, I briefly worked in Prof. Ernest Robb’s lab synthesizing calixarenes to characterize their properties. More substantially, Prof. Bose coordinated an UPTAM (Undergraduate Projects in Technology and Medicine) internship over Summer 1984 for me at Merck Research Laboratories in Rahway, NJ where my project involved the quantitation of platelet activating factor (PAF) in blood.

Q: Who were the faculty members or mentors who had the greatest influence on your career?

Dr. Hale: I remember being struck by what an excellent lecturer Prof. Robb was. That showed me early in my career how important it was to be able to engagingly communicate about chemistry and science, in general.

I am eternally grateful to Prof. Bose for seeing something in me and providing me the opportunity at Merck. Over the time of my summer internship, I realized that I could pursue a career in medicine (as an organic chemist) without necessarily being a physician. I was hired by Merck full-time on graduating from Stevens in 1985 and quite frankly already thought then that I had “made it”!

Q: Can you still remember where your laboratory or office was?

Dr. Hale: I vaguely remember the labs where chemistry research was conducted being on the 2nd floor – but it was so long ago!

Q: Is there a favorite spot in the department or on campus that you still remember?

Dr. Hale: One spot I’d characterize as “memorable” would be the A Building (Edwin A. Stevens Hall). I was one of maybe five or six students who took Organic Chemistry III with Prof. (Maghar) Manhas in a small classroom there that was only wide enough for one row of student desks. Prof. Manhas could be quite intimidating and you could not escape to a back row in the class to escape!

The education and training at Stevens is quite rigorous and really set me up to succeed after graduating in 1985. I remember taking advantage of Steven’s many non-academic offerings (playing intramural sports, being a member of a fraternity (Chi Psi), proximity to NYC) being a wonderful complement that spurred young me to persevere!

Q: How did your education/research in the department prepare you for a career in the pharmaceutical industry?

Dr. Hale: As I mentioned above, the summer I spent at Merck had a profound impact on me and set me on my career path. I had developed an interest in and aptitude for organic chemistry at Stevens and that set me up for a successful start for a career in the pharmaceutical industry.

Q: Is there a particular drug/technology or program, you helped develop that you're especially proud of?

Dr. Hale: From a medical impact perspective, it would be the discovery and development of the NK-1 receptor antagonist anti-emetic medications Emend® (aprepitant) and Emend® for Injection (fosaprepitant). These have had a profound impact on the lives of patients undergoing cancer chemotherapy.

From a basic drug discovery perspective, it would be our (Merck’s) investigation of S1P1 receptor agonists. The medicinal chemistry research I was privileged to lead ultimately inspired the design and development of the relapsing-remitting multiple sclerosis medications Mayzent® (siponimod), Zeposia® (ozanimod) and Velsipity® (etrasimod).

Q: What message would you like to leave for future generations of Chemistry and Chemical Biology department students?

Dr. Hale: Don’t underestimate the role of serendipity in science. While you can’t manufacture luck, all your education, training, persistence, dedication and hard work prepares you to recognize the “unexpected” when it comes along. The trick isn’t to get lucky – everyone will at some point – but to take advantage of it when it occurs.

“While you can’t manufacture luck, all your education, training, persistence, dedication and hard work prepares you to recognize the ‘unexpected’ when it comes along.”

Arvind Mathur.Dr. Arvind Mathur ’92

Former Vice President, Synthesis & Enabling Technologies, Bristol Myers Squibb

Accelerating the discovery and development of new medicines

Arvind Mathur retired as Vice President of Synthesis & Enabling Technologies in the Small Molecule Drug Discovery division at Bristol Myers Squibb (BMS) after a 35-year career with the company. Based in Princeton, New Jersey, Mathur played a pivotal role in advancing BMS’s mission to discover and develop innovative medicines that transform patients’ lives.

During his tenure at BMS, Mathur led strategic initiatives in synthetic chemistry and enabling technologies focused on accelerating the drug discovery process. He oversaw multidisciplinary teams dedicated to small-molecule therapeutics and was instrumental in building and maintaining a robust pipeline of treatments for serious diseases. His leadership extended across teams in Medicinal Chemistry, Process Chemistry, Analytical Chemistry and Radiochemistry.

One of Mathur’s significant achievements was the establishment of the Biocon Bristol Myers Squibb Research Center (BBRC) in Bangalore, India. Under his direction, the research center grew to employ more than 1,300 research scientists, covering the spectrum from discovery through the full development of innovative medicines.

His efforts supported BMS’s global reputation as a leader in the biopharmaceutical industry, particularly in the fields of oncology, immunology and cardiovascular disease. Mathur is recognized as a co-author of nearly 215 publications and holds 20 patents, underscoring his significant contributions to the scientific community.

Beyond his professional achievements, Mathur has contributed to his local community as a member of the Bridgewater–Raritan Board of Education. In this role, he was instrumental in reestablishing the STEM program and expanding Advanced Placement (AP) offerings within the school district. He also played a key role in managing the district’s extensive infrastructure and overseeing the school budget.

Mathur holds both a Master’s degree and a Ph.D. in Organic Chemistry from Stevens Institute of Technology, reflecting his strong academic foundation in the field.

Inaugural honoree · September 3, 2026

Q & A with Dr. Mathur

Q: What are your strongest memories of your time spent at Stevens?

Dr. Mathur: Stevens gave me the perfect training to self-learn and was empowered to take decisions. Dr. Bose always let me work on my ideas and take decisions related to instruments in the group. This kind of experience helped me in my career to “take and own” my decisions.

Q: What was the focus of your graduate/undergraduate research at Stevens?

Dr. Mathur: I first started in Dr. Bose’s group as an Analytical chemist and established and installed the first super conducting 200 MHz NMR that was bought from IBM instruments. I self-trained to manually operate and do 2D NMR working closely with Ad Bax who is the father of 2D NMR spectroscopy. My first paper was related to structural elucidation of a natural product. I later transitioned to organic chemistry for my Ph.D. This experience helped me to broaden my responsibilities in BMS to include all analytical groups apart from my organic chemistry groups.

Q: Who were the faculty members or mentors who had the greatest influence on your career?

Dr. Mathur: No doubt it was Dr. Bose who instilled the best practice as a scientist – the thirst to read the current literature and be on top of all trends.

Q: Can you still remember where your laboratory or office was?

Dr. Mathur: I was in room 308/310

Q: Is there a favorite spot in the department or on campus that you still remember?

Dr. Mathur: It was the Castle Point next to the Stevens Center. We had our marriage reception at the Stevens Center facility.

Q: How did your education/research in the department prepare you for a career in the pharmaceutical industry?

Dr. Mathur: The resources available to students were limited and we had to struggle to get solvents and chemicals. This prompted us to use whatever was available to make do.

Q: Is there a particular drug/technology or program, you helped develop that you're especially proud of?

Dr. Mathur: I played crucial role in advancing several drugs to market. For example, Dapagliflozin, Plavix and yet to come to market Milvexian. I actually take Dapa myself!!

Dapagliflozin lowers blood sugar in type 2 diabetes, reduces heart failure hospitalizations, and slows chronic kidney disease progression. Milvexian is an investigational antithrombotic agent aimed at reducing blood clot risks without significantly increasing major bleeding complications. Plavix (generic name: clopidogrel) is a widely approved, foundational antiplatelet medication used to prevent blood clots.

Q: What message would you like to leave for future generations of CCB department students?

Dr. Mathur: Dream big – aim for the stars and you will land on the moon. There is no substitute for working hard and developing soft skills and that will propel you higher responsibilities.

“I woke up every morning eager to go to work so that I can accelerate the time needed to deliver a drug ‘A day early’ to save a life.”

Birendra N. Pramanik.Dr. Birendra N. Pramanik ’77

Distinguished Fellow, Merck Research Laboratories, Retired

Advancing analytical chemistry and pharmaceutical discovery

Birendra N. Pramanik retired in 2010 as a Distinguished Fellow at Merck Research Laboratories, following a distinguished 30-year career in pharmaceutical research that began at Schering-Plough in 1980, prior to its merger with Merck & Co.

At Schering-Plough, Pramanik became a leading authority in mass spectrometry and structural analysis and helped establish state-of-the-art mass spectrometry and NMR facilities. Renowned for his expertise in the interpretation of mass spectra, he solved complex analytical problems that had long resisted resolution.

His contributions supported the discovery and development of numerous novel therapeutics, including the anti-allergy medicines Claritin and Clarinex; the cholesterol-lowering drugs Zetia and Vytorin; the antifungal Noxafil; the antiviral and anticancer agent Interferon alfa-2b; steroid-based anti-inflammatory products; and the immunotherapeutic Keytruda. Pramanik is an author or co-author of more than 140 publications and has presented over 150 talks at national and international meetings. He has also taught special courses at institutions including Columbia University and Stevens Institute of Technology.

His work has been recognized with numerous honors, including the American Chemical Society North Jersey Mass Spectrometry Section Regional Award in 2000, two President’s Awards at the company in 1983 and 1987, the Richardson-Vicks Chairman’s Award in 1980, and a Chinese Chemical Society Award in 2005–2006.

A dedicated philanthropist, Pramanik established endowed scholarship funds at Stevens Institute of Technology in memory of his mentor, Professor Ajay Kumar Bose, and Margaret Logan Bose. He also introduced scholarships at Parsippany High School and Parsippany Hills High School in honor of his parents.

Pramanik earned an M.Sc. in Chemistry in 1965 from Rajshahi University, now in Bangladesh. He completed his graduate studies at Stevens Institute of Technology under the mentorship of Professor Ajay K. Bose, earning an M.S. in 1973 and a Ph.D. in Organic Chemistry in 1977.

Pramanik attributes much of his professional success to the rigorous research training and professional values he acquired while working under Professor Ajay K. Bose at Stevens Institute of Technology.

Inaugural honoree · September 3, 2026

Q & A with Dr. Pramanik

Q: What are your strongest memories of your time spent at Stevens?

Dr. Pramanik: My strongest memory that I have during my graduate studies at Stevens was the news I received from a Stevens security guard in April 1971 that my family (wife, daughter, son and other family members) safely crossed the border into India and took shelter at a refugee camp. My graduate studies occurred at a difficulty time, while a war was raging in East Pakistan, and I did not have any contact with my family for about eight months (Sept. 1970-April 1971). The Stevens administration was aware of my situation. When a telegram came to Stevens from my brother in India with this news, the President’s office sent a security guard to deliver the message to me, while I was working at an Indian restaurant in New York City. I was overwhelmed with joy and happiness. The second most important memory was the successful defense of my dissertation in 1977 and receiving my Ph.D. degree.

Q: What was the focus of your graduate/undergraduate research at Stevens?

Dr. Pramanik: The title of my Ph.D. thesis was : “Some Stereospecific Steroid Transformations”. This work was published in Tetrahedron Letters, 1977, No. 23, pp. 1977-1980 and was dedicated to Professor R.B. Woodward on the happy occasion of his sixtieth birthday. Professor Woodward wrote an excellent letter praising the high quality of the work and highlighting its vital potential applications in the synthesis of amino steroids.

Also, included in the thesis was the work in mass spectrometry focusing on the development of novel methods to the analysis of multifunctional non-volatile organic molecules. An important highlight was the use of ammonium salts for the enhancement of molecular ions of the compounds. This work was published in Analytical Biochemistry in 1978. My association with Dr. Bose continued even after I left Stevens and our decades-long research collaboration resulted in 14 papers, some of which were cited nearly 300 times.

Q: Who were the faculty members or mentors who had the greatest influence on your career?

Dr. Pramanik: Faculty members who had the greatest influence on me were Professor Ajay K. Bose (mentor/advisor), Professor Maghar. S. Manhas, Professor Ashit K. Ganguly, Professor Ernest Robb, Professor Angelo A. Volpe, Professor Arthur Ritter, Professor Francis Clough, Professor J. M. van der Veen and Professor Frank Jones.

Q: Can you still remember where your laboratory or office was?

Dr. Pramanik: My lab was on the 3rd floor in the McLean Building, I shared two laboratories and supervised undergraduate research students as well UPTAM projects.

Q: Is there a favorite spot in the department or on campus that you still remember?

Dr. Pramanik: In front of McLean Building, there was a small sitting area where we used to gather for discussion with colleagues and friends including Sugi Sun, Fuji Sun, Shantu Amin and Bishambar Dayal. Some highly talented undergraduates used to join among them John Vincent, Charles Gluchowski, Robert Glagier, George Trainer, Albert Schwartz, Michael McGuire and James Labdon. Some of these students conducted research under UPTAM programs and went onto became medical doctors or some continued on to graduate programs including attending Harvard University after graduation.

Chandra and Arvind joined Dr. Bose’s group towards the end of my career at Stevens. Also, another undergraduate was George Young who worked with Professor J.M. van Der Veen. They all became highly successful in industrial employment. I am very proud of Arvind, Jeffrey and George for their achievements and generosity to give back to Stevens.

Q: How did your education/research in the department prepare you for a career in the pharmaceutical industry?

Dr. Pramanik: My Stevens education in synthetic organic chemistry along with my training in mass spectrometry, prepared me well to tackle complex analytical challenges when I joined Schering-Plough. I was able to solve major long-standing problems that eluded resolution for years. One such example was the structure characterization of highly complex oligosaccharide antibiotic, Everninomicin, published in Heterocycles, which was dedicated to Sir D.H.R. Barton on his 70th birthday. Over my career, I have developed deep expertise in the interpretation of MS spectra. Sir Derek Barton was highly pleased when he learned from Dr. Ashit Ganguly that I solved the structure of Everninomycin. Ashit, was Sir Derek’s student at Imperial College, London. Sir Derek was impressed and he wrote a letter of recommendation for my promotion to Schering-Plough’s highest scientific position, Distinguished Fellow.

Q: Is there a particular drug/technology or program, you helped develop that you're especially proud of?

Dr. Pramanik: I was involved in the development of many drugs: Allergy drugs, Claritin and Clarinex, anti-fungal drug Noxafil, Cholesterol lowering drugs, Zatia and Vytorin, anti-viral anticancer-interferon alpha-2b, as well as anti-inflammatory steroid products and amino glycosides.

Later in my career (1990), I started working on antibodies and generated monoclonal antibody spectra of anti-il-11, with molecular weight 146 kilo-dalton which was published. Furthermore, I had discussions on a project involving immunoglobulins that we received from Organon, a Dutch company Schering-Plough acquired around 2007. After the merger of Schering-Plough with Merck & Co. in 2009, Merck took over the project and developed the famous immune therapy medication Keytruda.

Q: What message would you like to leave for future generations of CCB department students?

Dr. Pramanik: My advice to the next generation of researchers is simple: be creative, learn your subject thoroughly, to the absolute best of your ability, and focus entirely on making meaningful contributions. Whether you enter industrial research or academia, you must prepare yourself to be a problem solver. In the professional world, what matters most is the tangible financial value and funding you can bring to your organization through your expertise and creativity. A Stevens education will certainly prepare you well to thrive.

Finally, quality is never a coincidence. It is the deliberate outcome of clear intention, disciplined effort, intelligent strategy, and an unyielding commitment to excellence.

“Quality is never a coincidence. It is the deliberate outcome of clear intention, disciplined effort, intelligent strategy, and an unyielding commitment to excellence.”
Student in a Stevens sweatshirt handling test tubes in a lab.

A Legacy That Continues

The Ajay Bose Hall of Distinction celebrates scientific discovery and mentorship at Stevens, with inaugural honorees paving the way for generations to follow.